Elranatamab + Tocilizumab for Multiple Myeloma

(CORE-MM Trial)

This trial tests a drug combination for multiple myeloma, a type of blood cancer that often recurs after treatment. Researchers aim to determine if adding tocilizumab can reduce cytokine release syndrome (CRS), a side effect that causes flu-like symptoms. Participants will receive the treatment in two phases to ensure safety and effectiveness. This trial may suit individuals whose multiple myeloma has returned after previous treatments, including lenalidomide and a specific type of antibody therapy, and who maintain manageable health overall. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot take strong or moderate inducers of CYP3A4 (a liver enzyme) during the study, and any changes to HIV medications should be made well before starting the trial. It's best to discuss your current medications with the study team.

Previous studies have shown that elranatamab is generally well-tolerated by patients with multiple myeloma, a type of blood cancer. Research indicates that about 13% of patients experienced cytokine release syndrome (CRS), where the body reacts strongly, often with flu-like symptoms. Most patients developed CRS after their first or second dose of treatment.

When combined with tocilizumab, a medication used to manage CRS, the safety of elranatamab was still under investigation. Tocilizumab, already approved by the FDA for other conditions, has a well-established safety profile. Another study found that combining elranatamab with a different drug led to a good response rate, demonstrating its potential effectiveness.

Elranatamab is unique because it introduces a new mechanism of action in the treatment of multiple myeloma. Unlike many current therapies that target cancer cells directly, elranatamab is a bispecific antibody that engages the body's immune system to attack the cancer by directing T-cells to the myeloma cells. This approach may offer a more targeted attack on the disease with potentially fewer side effects. Researchers are excited about its potential to enhance the body's natural defenses against multiple myeloma, offering hope for improved treatment outcomes.

Research has shown that elranatamab holds promise for treating relapsed or refractory multiple myeloma (RRMM), a type of blood cancer. In previous studies, 61% of patients responded to the treatment, with most seeing improvements in just over a month. Another study found that 65% of patients experienced a reduction in cancer activity. Additionally, 82% of those who responded maintained their improvement, demonstrating lasting benefits. In this trial, participants will receive tocilizumab, a medication that helps control inflammation, alongside elranatamab. This combination has been shown to keep side effects like cytokine release syndrome low, without reducing the treatment's effectiveness.¹²⁶⁷⁸